Clinical trials: Conjunctivitis
Ocular Itching, Ocular Allergy
Efficacy and Safety of PRO-118 Ophthalmic Solution in Allergic Conjunctivitis
The purpose of this study is to evaluate the efficacy and safety of four doses of PRO-118 ophthalmic solution ophthalmic solution compared with placebo, for the treatment of seasonal (SAC) and perennial (PAC) allergic…
- Conditions
- Ocular Itching, Ocular Allergy, Seasonal Allergic Conjunctivitis, Perennial Allergic Conjunctivitis
- Trial name
- PRO-118 (NCT01541904)
- Testing
- PRO-118 Ophthalmic Solution 0.015%, PRO-118 Ophthalmic Solution 0.015 %, PRO-118 Ophthalmic Solution 0.020 %
- Where
- 2 sites in Mexico
- Sponsor
- Laboratorios Sophia S.A de C.V.
Keratoconjunctivitis Sicca
A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Disease
The purpose of this study is to assess the safety and efficacy of Tavilermide Ophthalmic Solution compared with Placebo Ophthalmic Solution in treating the signs and symptoms of dry eye disease.
- Trial name
- NCT02665234
- Testing
- 1% Tavilermide Ophthalmic Solution
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Mimetogen Pharmaceuticals USA, Inc.
Bacterial Conjunctivitis
AL-15469A for the Treatment of Bacterial Conjunctivitis
The purpose of the study is to determine whether AL-15469A is safe and effective in the treatment of bacterial conjunctivitis.
- Trial name
- NCT00332293
- Testing
- Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5%, Moxifloxacin hydrochloride ophthalmic solution 0.5% as base
- Where
- United States
- Volunteers
- 695 people
- Sponsor
- Alcon Research
Conjunctivitis, Bacterial
Safety and Tolerability of PRO-143 Ophthalmic Solution in Healthy Volunteers.
Study to evaluate the safety and tolerability of PRO-143 solution ophthalmic in healthy volunteers.
- Trial name
- PRO-143 (NCT03698045)
- Testing
- PRO-143 Ophthalmic Solution
- Where
- Mexico
- Volunteers
- healthy volunteers welcome
- Sponsor
- Laboratorios Sophia S.A de C.V.
Allergic Conjunctivitis
Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers
The purpose of this study is to evaluate the safety of a novel contact lens in healthy normal volunteers
- Trial name
- NCT00569777
- Testing
- K-Lens (generic name not established) and Ketotifen
- Where
- 3 sites in United States
- Volunteers
- 310 people, healthy volunteers welcome
- Sponsor
- Vistakon Pharmaceuticals
Allergic Rhinitis Due to House Dust Mite, Allergic Conjunctivitis Due to Dermatophagoides Farinae
Noninterventional Study on Tolerability and Safety of One Strength Updosing With Novo-Helisen Depot House Dust Mites
The goal of this non-interventional study is to investigate the safety and tolerability of a new simplified up-dosing schedule for Novo-Helisen Depot.
- Conditions
- Allergic Rhinitis Due to House Dust Mite, Allergic Conjunctivitis Due to Dermatophagoides Farinae, Allergic Conjunctivitis Due to Dermatophagoides Pteronyssinus, Allergic Asthma Due to Dermatophagoides Farinae
- Trial name
- NOVUS-UP (NCT07096440)
- Volunteers
- 105 people
- Sponsor
- Allergopharma GmbH & Co. KG
Keratoconjunctivitis, Conjunctivitis
Phase III Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis
To investigate the efficacy and safety of FK506 ophthalmic suspension on eye symptoms in patients with vernal keratoconjunctivitis
- Trial name
- NCT00567762
- Testing
- FK506
- Where
- 8 sites in Japan
- Volunteers
- 56 people
- Sponsor
- Astellas Pharma Inc
Allergic Conjunctivitis
Efficacy and Safety of AL-4943A Ophthalmic Solution in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model
The purpose of this study was to assess the safety and efficacy of AL-4943A ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis using the Conjunctival Allergen Challenge (CAC) model.
- Trial name
- NCT01479374
- Testing
- AL-4943A ophthalmic solution, AL-4943A vehicle, Olopatadine hydrochloride ophthalmic solution, 0.2%
- Volunteers
- 397 people
- Sponsor
- Alcon Research
Allergic Conjunctivitis
Safety Study for Bepotastine Besilate Ophthalmic Solution in Normal Volunteers
Safety study for bepotastine besilate ophthalmic solution in normal volunteers
- Trial name
- NCT00586625
- Testing
- Bepreve
- Volunteers
- 861 people, healthy volunteers welcome
- Sponsor
- Bausch & Lomb Incorporated
Dry Eye Syndrome
Study of SkQ1 as Treatment for Dry-eye Syndrome
The purpose of this study is to evaluate whether SkQ1 ophthalmic solutions are safe and effective compared to placebo for the treatment of the signs and symptoms of dry eye syndrome.
- Trial name
- VISTA-1 (NCT03764735)
- Testing
- Low Dose - SkQ1, High dose - SkQ1, SkQ1 (Vehicle)
- Where
- 7 sites in United States
- Volunteers
- 452 people
- Sponsor
- Mitotech, SA
Conjunctivitis, Allergic
A Study of the Effects of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms (Study P04209)
This study was a double-blind, placebo-controlled, cross-over, single-center study of desloratadine 5 mg or placebo in subjects 18 years of age or older with a history of seasonal allergic rhinoconjunctivitis.
- Trial name
- NCT00311844
- Testing
- desloratadine
- Volunteers
- 41 people
- Sponsor
- Organon and Co
Dry Eye Disease
Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease
Phase 1/2, first-in-human, 2-part study to assess topically administered eyedrops of INV-102 during 2-week repeat dosing in subjects with moderate symptomatic dry eye disease.
- Trial name
- NCT05586152
- Testing
- INV-102, Vehicle
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Invirsa, Inc.
Allergic Conjunctivitis
AGN-229666 for the Treatment of Allergic Conjunctivitis
This study will evaluate the safety and efficacy of AGN-229666 for the treatment of allergic conjunctivitis.
- Trial name
- NCT01754766
- Testing
- AGN-229666, vehicle of AGN-229666
- Where
- Japan
- Volunteers
- 90 people
- Sponsor
- Allergan
Allergic Conjunctivitis
A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model
To evaluate the efficacy of Bilastine Ophthalmic Solution (0.2%,0.4%,0.6%) compared to vehicle for the treatment of the signs and symptoms of allergic conjunctivitis
- Trial name
- NCT03231969
- Testing
- Bilastine 0.2%, Bilastine 0.4%, Bilastine 0.6%
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Faes Farma, S.A.
Viral Conjunctivitis
ADenoVirus Initiative Study in Epidemiology in Spain
The objectives of this study is to assess the characteristics and frequency of adenovirus conjunctivitis in a population of male and female patients from one year of age who present signs and symptoms of acute conjunctivitis.
- Trial name
- NCT02254330
- Where
- 25 sites in Spain
- Volunteers
- 386 people
- Sponsor
- NicOx
Dry Eye Syndromes
Evaluation of the Safety and Effectiveness of the Oculeve Intranasal Lacrimal Neurostimulator in Patients With Dry Eye
The purpose of this study was to evaluate the safety and effectiveness of the Intranasal Tear Neurostimulator applied intranasally compared with the same device applied extranasally (control) in treating the symptoms of dry eye…
- Trial name
- NCT02313454
- Testing
- Intranasal Tear Neurostimulator
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Allergan
Conjunctivitis, Seasonal Allergic, Conjunctivitis, Giant Papillary
A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5%
The objective of this study is to identify any adverse events or adverse drug reactions through post-marketing surveillance under routine clinical practice
- Conditions
- Conjunctivitis, Seasonal Allergic, Conjunctivitis, Giant Papillary, Inflammation
- Trial name
- NCT01437982
- Testing
- Loteprednol Etabonate, Prednisolone Acetate 1% Oph Susp
- Where
- South Korea
- Volunteers
- 140 people
- Sponsor
- Bausch & Lomb Incorporated
Allergic Conjunctivitis
Olopatadine Hydrochloride Ophthalmic Solution Study in Chinese Subjects
The purpose of this study is to evaluate olopatadine 0.2% QD (once per day) compared to olopatadine 0.1% BID (twice per day) in the treatment of ocular itching associated with allergic conjunctivitis.
- Trial name
- NCT02322216
- Testing
- Olopatadine Hydrochloride Ophthalmic Solution 0.2%, Olopatadine Hydrochloride Ophthalmic Solution 0.1%, Olopatadine 0.2% Vehicle
- Volunteers
- 383 people
- Sponsor
- Alcon Research
Bacterial Conjunctivitis, Acute
Efficacy Maxinom® And Maxitrol® in Reducing The Signs And Symptoms Of Acute Bacterial Conjunctivitis
The primary objective of this study is to evaluate, through clinical parameters, the effectiveness of your medicine topic Maxinom ® (dexamethasone, neomycin and polymyxin B - Union Chemicals), comparing it to the topical…
- Trial name
- NCT01227863
- Testing
- MAXINOM®, Maxitrol®
- Where
- Brazil
- Volunteers
- 70 people
- Sponsor
- Azidus Brasil
Acute Adenoviral Conjunctivitis
FST-100 in the Treatment of Acute Adenoviral Conjunctivitis
This randomized, double masked, multi-center study is being conducted to support the safety and efficacy of FST-100 for the treatment of acute adenoviral conjunctivitis.
- Trial name
- NCT01470664
- Testing
- FST-100, FST-100 (Component #1), FST-100 Vehicle
- Where
- 2 sites in United States, India
- Volunteers
- 176 people
- Sponsor
- Shire